news
Blocking SLAMF6 enables T cells to kill leukaemia cells
Researchers have discovered a surface protein that helps acute myeloid leukaemia cells evade the immune system, offering potential insights to aid the development of new treatments.
List view / Grid view
Immunotherapy
news
New CAR T therapy targets solid tumours safely and effectively
USC researchers have engineered CAR T cells to deliver a dual protein therapy that targets solid tumours – offering hope for cancers previously resistant to treatment.
news
Senolytic drug combo boosts cancer immunotherapy and reduces side effects
Researchers have discovered that targeting immune cell ageing can overcome resistance to head and neck cancer treatment.
news
Tiny models, powerful insights: how organoids are driving precision oncology
A new review has highlighted how three-dimensional organoid models are transforming cancer research by replicating the complexity of human tumours – bringing precision oncology closer to the clinic.
article
Why scientists are targeting the gut to treat peanut allergy
A new oral immunotherapy could change how peanut allergy is treated, targeting the gut to retrain the immune system and reduce the risk of life-threatening reactions. INP20’s nanoparticle technology promises a safer, more precise approach that could replace lifelong avoidance with lasting tolerance.
news
Anti-linker antibodies: a universal key for CAR-T detection
Every new CAR-T needs a new detection tool – until now. Anti-linker antibodies could change how researchers develop and track these therapies.
news
Melanoma research: targeted drug duo reactivates immune response
Researchers at Sutter’s California Pacific Medical Center have discovered a potential new treatment strategy for melanoma patients who stop responding to immunotherapy.
news
Tumour stress drives T cell exhaustion – antioxidants may reverse it
A new research study has discovered that targeted antioxidants could restore T cell function – offering a potential boost for cancer immunotherapies like CAR-T.
article
CAR T’s biggest hurdle: solving the toxicity problem
CAR T therapies are saving lives, but toxicities such as CRS and ICANS remain a major barrier. What will it take to overcome them?
article
Challenges in developing robust potency assays for ADCs
Developing robust potency assays for Antibody-Drug Conjugates (ADCs) is crucial for ensuring their clinical success, but designing assays that meet both technical and regulatory standards is challenging. Here, Abzena’s CSO Campbell Bunce explores the complexities of assay development and the importance of ensuring accuracy, consistency and regulatory alignment for ADCs…
article
Lupus reimagined: targeting the cause, not just the symptoms
Engineered cell therapies are offering a potential new way to treat lupus – not by suppressing symptoms, but by reprogramming the immune system itself. For the first time, lasting remission looks like a real possibility.
news
Fuelling immunity: glucose helps T cells fight cancer better
A new study from the Van Andel Institute shows that glucose not only fuels T cells but also strengthens their internal signalling and cancer-fighting capabilities –offering a potential route to improved immunotherapies.
news
New lipid nanoparticle boosts mRNA delivery fivefold in cancer study
Japanese researchers have engineered a new lipid nanoparticle that delivers mRNA to cells five times more effectively, resulting in stronger immune responses and tumour suppression in mice.
news
Smart nanogels help CAR-T cells penetrate tumours
Researchers in China have developed a next-generation CAR-T cell therapy armed with nanogels that can penetrate the dense barriers of solid tumours. This addresses a major limitation in the treatment of solid cancers with immunotherapy.
news
Dual CAR-T cell therapy targets T-ALL with precision
A new dual CAR-T cell therapy targeting two tumour-specific proteins in T-cell Acute Lymphoblastic Leukaemia (T-ALL) has been developed – meaning effective treatment for this aggressive blood cancer could soon become a reality.
